Ad is loading...
CRSP
Price
$47.25
Change
+$0.40 (+0.85%)
Updated
Nov 15 closing price
92 days until earnings call
IGXT
Price
$0.17
Change
-$0.00 (-0.00%)
Updated
May 16 closing price
Earnings call today
Ad is loading...

CRSP vs IGXT

Header iconCRSP vs IGXT Comparison
Open Charts CRSP vs IGXTBanner chart's image
CRISPR Therapeutics AG
Price$47.25
Change+$0.40 (+0.85%)
Volume$3.13M
CapitalizationN/A
IntelGenx Technologies
Price$0.17
Change-$0.00 (-0.00%)
Volume$37.23K
CapitalizationN/A
CRSP vs IGXT Comparison Chart
Loading...
CRSP
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
View a ticker or compare two or three
VS
CRSP vs. IGXT commentary
Nov 18, 2024

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is CRSP is a StrongSell and IGXT is a Buy.

COMPARISON
Comparison
Nov 18, 2024
Stock price -- (CRSP: $47.25 vs. IGXT: $0.17)
Brand notoriety: CRSP and IGXT are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: CRSP: 234% vs. IGXT: 100%
Market capitalization -- CRSP: $4.03B vs. IGXT: $29.17M
CRSP [@Biotechnology] is valued at $4.03B. IGXT’s [@Biotechnology] market capitalization is $29.17M. The market cap for tickers in the [@Biotechnology] industry ranges from $472.8B to $0. The average market capitalization across the [@Biotechnology] industry is $2.66B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

CRSP’s FA Score shows that 0 FA rating(s) are green whileIGXT’s FA Score has 1 green FA rating(s).

  • CRSP’s FA Score: 0 green, 5 red.
  • IGXT’s FA Score: 1 green, 4 red.
According to our system of comparison, IGXT is a better buy in the long-term than CRSP.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

CRSP’s TA Score shows that 4 TA indicator(s) are bullish.

  • CRSP’s TA Score: 4 bullish, 6 bearish.

Price Growth

CRSP (@Biotechnology) experienced а -8.47% price change this week, while IGXT (@Biotechnology) price change was 0.00% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -8.58%. For the same industry, the average monthly price growth was -5.90%, and the average quarterly price growth was -0.16%.

Reported Earning Dates

CRSP is expected to report earnings on Feb 18, 2025.

IGXT is expected to report earnings on Nov 18, 2024.

Industries' Descriptions

@Biotechnology (-8.58% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
CRSP($4.03B) has a higher market cap than IGXT($29.2M). IGXT YTD gains are higher at: 20.905 vs. CRSP (-24.521). IGXT has higher annual earnings (EBITDA): -8.16M vs. CRSP (-335.17M). CRSP has more cash in the bank: 484M vs. IGXT (772K). IGXT has less debt than CRSP: IGXT (16.5M) vs CRSP (231M). CRSP has higher revenues than IGXT: CRSP (200M) vs IGXT (1.05M).
CRSPIGXTCRSP / IGXT
Capitalization4.03B29.2M13,812%
EBITDA-335.17M-8.16M4,110%
Gain YTD-24.52120.905-117%
P/E RatioN/AN/A-
Revenue200M1.05M19,029%
Total Cash484M772K62,694%
Total Debt231M16.5M1,400%
FUNDAMENTALS RATINGS
CRSP vs IGXT: Fundamental Ratings
CRSP
IGXT
OUTLOOK RATING
1..100
6950
VALUATION
overvalued / fair valued / undervalued
1..100
63
Fair valued
89
Overvalued
PROFIT vs RISK RATING
1..100
93100
SMR RATING
1..100
91100
PRICE GROWTH RATING
1..100
7452
P/E GROWTH RATING
1..100
856
SEASONALITY SCORE
1..100
50n/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

CRSP's Valuation (63) in the Biotechnology industry is in the same range as IGXT (89) in the null industry. This means that CRSP’s stock grew similarly to IGXT’s over the last 12 months.

CRSP's Profit vs Risk Rating (93) in the Biotechnology industry is in the same range as IGXT (100) in the null industry. This means that CRSP’s stock grew similarly to IGXT’s over the last 12 months.

CRSP's SMR Rating (91) in the Biotechnology industry is in the same range as IGXT (100) in the null industry. This means that CRSP’s stock grew similarly to IGXT’s over the last 12 months.

IGXT's Price Growth Rating (52) in the null industry is in the same range as CRSP (74) in the Biotechnology industry. This means that IGXT’s stock grew similarly to CRSP’s over the last 12 months.

IGXT's P/E Growth Rating (6) in the null industry is significantly better than the same rating for CRSP (85) in the Biotechnology industry. This means that IGXT’s stock grew significantly faster than CRSP’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
CRSP
RSI
ODDS (%)
Bearish Trend 3 days ago
87%
Stochastic
ODDS (%)
Bullish Trend 3 days ago
72%
Momentum
ODDS (%)
Bearish Trend 3 days ago
80%
MACD
ODDS (%)
Bearish Trend 3 days ago
83%
TrendWeek
ODDS (%)
Bearish Trend 3 days ago
83%
TrendMonth
ODDS (%)
Bearish Trend 3 days ago
86%
Advances
ODDS (%)
Bullish Trend 11 days ago
81%
Declines
ODDS (%)
Bearish Trend 4 days ago
85%
BollingerBands
ODDS (%)
Bearish Trend 3 days ago
90%
Aroon
ODDS (%)
Bullish Trend 3 days ago
77%
View a ticker or compare two or three
Ad is loading...
CRSP
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
FACVX36.14-0.10
-0.28%
Fidelity Advisor Convertible Secs A
FSEPX13.20-0.15
-1.12%
Fidelity Advisor Sustainable U.S. Eq M
FCPGX34.48-0.59
-1.68%
Fidelity Small Cap Growth
AGGDX12.90-0.22
-1.68%
American Century Focused Global Gr R6
GSTRX9.91-0.23
-2.27%
Goldman Sachs Strategic Growth R

IGXT and

Correlation & Price change

A.I.dvisor tells us that IGXT and ACET have been poorly correlated (+28% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that IGXT and ACET's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To IGXT
1D Price
Change %
IGXT100%
N/A
ACET - IGXT
28%
Poorly correlated
-9.82%
DTIL - IGXT
27%
Poorly correlated
-1.04%
EDIT - IGXT
25%
Poorly correlated
-3.97%
CRSP - IGXT
24%
Poorly correlated
+0.85%
BCRX - IGXT
24%
Poorly correlated
-5.64%
More